用选择性和综合性部剖析治疗的节点阳性口腔状细胞癌的瘤学结果
Jan Oliver Voss1,2, Lea Freund1, Felix Neumann1
1Department of Oral and Maxillofacial Surgery Charité-Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin Humboldt-Universität zu Berlin and Berlin Institute of Health, Augustenburger Platz 1 13353, Berlin, Germany.
BioMed research international
|July 19, 2024
概括
对于具有阳性淋巴结的口腔状细胞癌 (OSCC),全面部剖析 (CND) 和选择性部剖析 (SND) 似乎都是可行的治疗选择,在生存结果上没有显著差异.
科学领域:
- 在瘤学瘤学.
- 头部和部手术 头部和部手术
- 口腔癌研究 在口腔癌研究.
背景情况:
- 选择性部剖析 (SND) 是临床结节阴性 (cN0) 部口腔状细胞癌 (OSCC) 的标准.
- 临床结节阳性 (cN+) OSCC部的治疗包括SND或全面部解剖 (CND),目前关于最佳方法的争论仍在进行中.
研究的目的:
- 在患有OSCC和临床结节阳性 (cN+) 部的患者中,比较CND与SND的疗效.
- 在这个患者队列中确定影响整体生存 (OS) 和无病生存 (DFS) 的独立风险因素.
主要方法:
- 74名OSCC患者的回顾性分析,临床 (cN+) 和病理 (pN+) 阳性宫淋巴结 (LNs).
- 在2010-2019年期间,患者接受了CND或SND治疗,清晰的部水平分类.
- 考克斯回归分析用于评估生存结果和风险因素.
主要成果:
- 在CND和SND之间没有发现关于整体存活率 (OS) 或无病存活率 (DFS) 的统计学上显著差异.
- 区域性复发率是可比的:CND为5.77%,SND为9.09%.
- 囊外扩散 (ECS) 和男性性别被确定为较差的OS的独立风险因素;pT阶段和ECS是DFS的独立风险因素.
结论:
- 对于被诊断患有OSCC和病理阳性淋巴结 (pN+) 的选择患者,CND和SND都可被认为是可行的治疗选择.
- 治疗决策应考虑患者特定的因素,包括pT阶段和外囊扩散 (ECS) 的存在.
相关概念视频
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:21Cancer Survival Analysis
336
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
336